Latest Period
Q2 2026
Security Snapshot
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) Institutional Ownership
CUSIP: 09075P204
13F Institutional Holders and Ownership History from Q1 2025 to Q2 2026
Institutions Reporting
12
Shares (Excl. Options)
368,781
Price
$1.41
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- BTAI on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 368,781
- Total 13F value
- $511,836
- Portfolio coverage rank
- 0%
- Share change
- +136,108
- Value change
- +$191,913
- Number of holders
- 12
- Shares outstanding
- 21,847,524
- SEC-reported price per share
- $0.88
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 09075P204.
- 12 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 40 to 12 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $7,276,207 to $511,836.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 12 institutions filings for Q2 2026.
Security key
09075P204
Latest holder period
Q2 2026
13F holders
12
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
BTAI full holder history
BioXcel Therapeutics, Inc. SEC filings
BioXcel Therapeutics, Inc. company facts
BioXcel Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09075P204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
BTAI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| INTEGRATED CORE STRATEGIES (US) LLC | 8.4% | +64% | $3,762,144 | +$1,654,635 | 1,835,192 | +79% | Millennium Management LLC | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC | 5% | -50% | $564,737 | -$9,229,922 | 288,131 | -94% | Armistice Capital, LLC | 31 Mar 2025 |
As of 30 Jun 2026, 12 institutional investors reported holding 368,781 shares of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI). This represents 1.7% of the company’s total 21,847,524 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Latest
Q2 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 368,781 | $511,836 | +$191,913 | $1.41 | 12 |
| 2026 Q1 | 5,441,014 | $7,276,207 | +$2,473,613 | $1.34 | 40 |
| 2025 Q4 | 3,538,520 | $5,667,324 | +$1,743,166 | $1.60 | 42 |
| 2025 Q3 | 2,342,780 | $5,992,669 | +$4,499,749 | $2.56 | 35 |
| 2025 Q2 | 603,081 | $1,090,541 | +$395,829 | $1.81 | 33 |
| 2025 Q1 | 378,983 | $769,811 | +$769,716 | $2.03 | 31 |